Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer

LESSONS LEARNED. Vandetanib at a dose of 300 mg orally every day plus bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8, and 11 could be administered safely. Assessing outcomes in 17 patients with medullary thyroid cancer, investigators considered the combination to be more difficult to administe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Del Rivero, Jaydira, Edgerly, Maureen, Ward, Jean, Madan, Ravi A., Balasubramaniam, Sanjeeve, Fojo, Tito, Gramza, Ann W.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324636/
https://ncbi.nlm.nih.gov/pubmed/30297385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0452
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados